Very happy to share our technical report in Methods in Cell Biology describing our protocols to prepare and test CAR Tc in vivo. A special thanks to our former colleagues Anne Fåne and Marit Myhre for their fantastic work over the years!
Interview about combination immunotherapy from Anna Winge-Main
Nadia Mensali will give a presentation
Nadia Mensali has been invited by the Hellenic Society of Gene Therapy
and Regenerative Medicine to give a presentation:
"Design and validation of CAR directed against osteosarcoma"
"Gene and Cell Therapies: New Perspectives for old diseases - Web Event" on Friday 26 November. More information can be found here
PIVAC is still alive!
Thanks to the Local Organizing Committee & the International Scientific Committee for this fantastic PIVAC21 meeting in beautiful Granada!
We are happy to share our new publication about a modified version of PD-1 receptor, or how to turn something negative to an enhancing molecule. There have been a few reports this year showing technologies similar to ours, suggesting that interest for associated molecules to increase the binding might represent a solution to improve cell -based therapy. We thank all co-authors and of course our support: Helse Sør Øst, The Research Council of Norway and The Norwegian Cancer Society
Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors
Circulating Tumor Cell Persistence Associates with Long-TermClinical Outcome to a Therapeutic Cancer Vaccine inProstate Cancer
Ingrid Jenny Guldvik, Lina Ekseth, Amar U. Kishan, Andreas Stensvold, Else Marit Inderberg and Wolfgang Lilleby
Congratulations to Synne !
We are very proud of Synne Halvorsen Hougsnæs who succesfully defended her Master of Science in Biotechnology:
"CMV-specific Immune Responses Induced by Dendritic Cell Vaccines in Glioblastoma patients
And Clinical Benefit"
The normal protocol was respected:
Defense Flowers Cake
Anna Winge-Main and ASCO-2021
Congratulation to Clara, our future colleague!
Clara has successfully defended her Master thesis today and will join us next week.
We now know that one should be careful when selecting LB medium.
Credit: C. Forcados laptop at OCCI social area
Our method to clone CAR from hybridoma is finally cited in Pubmed:
More impotrantly it also present the first anti-Iglambda CAR:
10th World Congress of Melanoma/17th EADO Congres
Anna Winge-Main speaks at the session “Navigating Early-Stage Melanoma: Systemic Treatment Today and in the Future?” at the 10th World Congress of Melanoma/17th EADO Congress Industry Satellite Symposium 15th of April 2021
More information here
News Course on advanced therapy for EATRIS
Find out more about this excellent training program of ADVANCE
Credit: ADVANCE, linkedIN
Jubileumsintervju Inven2 10 år: Else Marit Inderberg – Inven2
Inven2 celebrates 10 years of collaboration with leading senior researchers bringin new products and services on market. Therefore, find out more informations about Dr. Else-Marit Inderberg's (group leader and head of immunomonitoring) interview here !
Else Marit Inderberg på laben. Foto: Elisabeth Kirkeng Andersen.
We are happy to welcome our new labmate : Seahorse !
The Seahorse XFe96 Analyzer (Agilent) measures the oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) of live cells in a 96-well plate format.
OCR and ECAR rates are key indicators of mitochondrial respiration and glycolysis as well as ATP production rate. Together these measurements will provide a clear view of cellular metabolic function in cultured cells such as Chimeric Antigen Receptor (CAR)- and T-cell Receptor (TCR)-modified cells !
More informations here !
Credit: Janne Nestvold (OCCI)
Solveig Mjelstad Olafsrud (Engineer) and Benjamin Caulier (Postdoc) will take care of it !
We are looking for a motivated Master student !
Immunotherapy & Biotechnology: Validation of humanized Chimeric Antigen Receptors targeted against solid tumour
A Master position is available for 2021 at the Unit of Translational Research, Department of Cellular Therapy, Oslo University Hospital (OUS) Radiumhospitalet under the supervision of Sébastien Wälchli (Senior researcher, group leader).
We offer: (1) a position in a dynamic environment within a modern/fully equipped facility (Oslo Cancer Cluster Incubator next to Radium hospital) and (2) the possibility to use advanced technology.
Successful candidates might be sent to an international conference.
Find out more here !
Any questions about the position can be sent to the following e-mail address: email@example.com
Virtual Event: What Does it Take to Impact Innovation?
This is how lab discussions emerge ;)
Here is Patrik Vernhoff (Postdoc NFR, our favorite biostatistician !) air-presenting vanishing expression profil on PCA.
Don't miss the journal club of Monday, 14th of September 2020.
Benjamin CAULIER, Postdoc, will present an article published in Immunity that deals with sustainability of CAR expression and response persistence using Ubiquitination modifications.
Credits: From Wentao Li et al:, Article in Immunity Volume 53, ISSUE 2, P456-470.e6, August 18, 2020
The journal club will take place in the usual 5th floor meeting room after the lab meeting (around 12h). See you there !
The Translational Research Unit will present some papers at the Immunology Journal Club on Friday 4th of September 2020 !
Hakan Köksal will present: Designed protein logic to target cells with precise combinations of surface antigens (Marc J. Lajoie et al., 2020) (https://science.sciencemag.org/content/early/2020/08/19/science.aba6527.full)
Nadia Mensali will present: An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma ( Ugur Sahin et al., 2020) (https://www.nature.com/articles/s41586-020-2537-9)
The Zoom link will be uptaded soon, make sure to schedule this event in your agenda !
The Norwegian biotech Zelluna Immunotherapy, based on a licence from our Translational Research Unit (Group leaders: Else Marit Inderberg and Sebastien Wälchli's group), received NOK 83 million to pursue their development on TCR-redirected NK cells !
We are very happy that an innovation developped five years ago by the early team (G. Gaudernack, G. Kvalheim, EM Inderberg and S. Wälchli) is now being developed as a therapeutic product. We thank our co-workers for their hard work, Inven2 for their support in the commercial development, and NFR, Helse Sør-Øst and Kreftforeningen for their financial support and guidance.
The team in Boston concluded that lobster is better than business:
The concept (with the old name):
Design: P. Dillard
Find more about this here !
New review on TCR therapy against melanoma
We published a new review in Scandinavian Journal of Immunology on how to adapt TCR redirected T-cells therapy to fight melanoma!
Make sure to have a look here!
We published a review on putative targets in ovarian cancer for CAR therapy in Scandinavian Journal of Immunology! Make sure to have a look here!
We published a new article in BMC Biotechnology on how to use colorectal cyst as a tool for the pre-clinical development of CAR T-cells.
Make sure to check the article here!
Hakan Köksal successfully defended his Ph.D. entitled “Novel designs and approaches in CAR T cells” Thursday 28th May.
All of his colleagues are proud of his work and his achievements!
M.Sc Hakan Köksal at Institute of Clinical Medicine will be defending the thesis “Novel designs and approaches in CAR T cells” for the degree of PhD (Philosophiae Doctor).
Due to the current pandemic situation, the University of Oslo is closed and the public defence will be held as a video conference over Zoom here.
The defence will follow regular procedure as far as possible, hence it will be open to the public and the audience can ask ex auditorio questions when invited to do so.
Else Marit Inderberg and Nadia Mensali took part in a paper showing the treatment of posttransplantation lymphoproliferative disease by using retransplantation, make sure to check it here!
Finally, Nicholas Casey published recently a paper on the use of RNAi with TCR transfer to enhance safety and efficiency. Follow the guide!
We participated to the EATRIS annual meeting in Lisbon and presented our work. We thank all the team for their great work and their commitment in this infrastructure.
Sympathetic improvement of cancer vaccine efficacy
Full text can be found here
A recent article in Nature Immunology showed a new type of T-cells that could improve cell-based therapies.
Forskning has asked Else Marit her opinion about it and about the latest developments in this field. Make sure to have a look here!
A new review from Else Marit Inderberg and Sebastien Wälchli was published in Cancer Immunology, Immunotherapy. The review described how we can isolate and identify therapeutic TCRs from long-term surviving patients.
Make sure to have a look here!
Amanda Ruud defended her Master at the University of Oslo, Wednesday (18/12). Her thesis title was: "Identification and pre-clinical assessment of patient-derived TCRs for solid tumor immunotherapy"
Pierre won the award with his talk entitled: "Targeting telomerase with an MHC class II restricted TCR for cancer immunotherapy". Make sure to have a look at his abstract!
We will be at the annual NSI meeting, the 29th of November!
We will talk about our latest progress on CAR and TCR therapy. See you there!
Sebastien Wälchli was invited at the 1st meeting ASEICA-ASPIC on Immunotherapy to talk about TCR based ACT.
Sebastien Walchli, a group leader in our department, gave an interview to the technical transfer office of the hospital: Inven2.
Make sure to check it here !
Emmanuelle Benard will present our last improvements on CD37 CAR T-cell therapy. Make sure to check the program of the conference and her abstract !
Nadia Mensali and Marit R. Myhre published a new study entitled: "Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy". A copy of the study published in Cancer Immunology, Immunotherapy can be found here.
We were at the last PIVAC (Progress in Vaccination Against Cancer) 2019 !
Else Marit and Hedvig presented our most recent developments !
Make sure to check their abstracts !
Yesterday Lizet Baken successfully defended her Bachelor Thesis at the Avans University of Applied Sciences.
Part of this thesis was performed in our lab where she has been working on an anti-Ig-lambda CAR.
Congratulations Lizet, we are all very proud of you!
Our collaborators published a new paper on TIGIT and PD-1 as markers of reduced effector function of T-cells in B-cell lymphoma.
Make sure to have a look here !
Gunnar Kvalheim, Hakan Köksal and Pierre Dillard will be at the next AACR meeting (29th of March to 3rd of April, Atalanta) to talk about new developments in CAR.
Hakan will present a novel combination method for IGKCAR that prevents B-cell aplasia.
Pierre will present the pre-clinical validation of CD37CAR, an alternative to CD19CAR.
Make sure to have a look!
Pierre Dillard will present our rescent work on the pre-clinical validation of CD37 CAR T-cells in Barcelona (11 - 13 March 2019).
Make sure to take a look at the abstract and at the conference website !
We published a new paper on redirected NK cells, transduced with TCR.
Make sure to take a look at the paper here !
New publication from Nadia Mensali in OncoImmunology.
This article decribe the loading of MCHI and II molecules by using CD74 constructs.
Make sure to check it out here!
We published a new review on the treatment of osteosarcoma by CAR therapy.
Make sure to have a looke here !
Emmanuelle Benard who did her PhD in Biophysics and Immunology in Marseille, just joined us !
She will be in charge of the development of new CAR T-cells.
We had our first JOVE shooting on a new metod to generate spheroid for CAR T-cells screening.
Make sure to give it a look (once it is out) !
PIVAC 2018 was held in Oslo, co-organized by the department of Cell Therpay. The conference permitted to share new advance in the field of vaccination and future prospects for immunotherapy.
Pierre Dillard will attend the 2018 meeting of the American Association for Cncer Research (AACR). He will present our recent work on universal killer, make sure to have a look !
Human c-SRC kinase (CSK) overexpression makes T cells dummy
Patient safety upon immunotherapy treatment is a challenge that still need to be adressed.
In this publication we report how by affecting c-SRC kinase we can make T-cells "dummy": effector cells are still able to recognize and bind to the target but unable to carry on with their activation. This mechanism could potentially open the way for a safe-lock system permitting to reduce off-target toxicity.
Image from: Ellen Tenstad/Science Shaped
Nadia Mensali was awarded with the presentation prize for her talk on the Universal Killer! See below to learn more
Nadia Mensali and Pierre Dillard will attend the 2017 meeting of the Society for ImmunoTherapy of Cancer (SITC). They will present our recent work on universal killer and CD4 Adoptive cell therapy, make sure to have a look !
Our team published a new paper about using TCR in CAR design, make sure to have a look here !
The new Oslo Cancer Cluster presentation book is out!
Have a look here:
Marit Renee Myhre has been selected to give a talk at the 17th International Conference on Progress in Vaccination Against Cancer (PIVAC 2017) in Loutraki, Corinth, Greece
She will present our latest work on our new CD4-based therapy, make sure to have a look at the abstract if you want to learn more !
Our team has published a new paper in Translational Cancer Research:
New publication in our team: therapeutic T-cell receptors in healthy donor blood, is safety predictable? by Hakan Köksal and Sébastien Wälchli.
They are commenting a paper published in 2017 in Blood by Jahn et al. that presents a novel TCR-based therapy trageting intracellular transcription factor. Make sure to have a look at both papers!